Bioqual Q3 2026 Earnings Report

Bioqual EPS Results

• Actual EPS: -$0.84
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bioqual Revenue Results

• Actual Revenue: $9.84 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bioqual Announcement Details

• Quarter: Q3 2026
• Date: 4/21/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Bioqual (OTCMKTS:BIOQ), Inc. is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds. The company’s facilities include vivarium capabilities, tissue culture laboratories and bioanalytical suites configured to meet regulatory standards. Bioqual’s scientific team collaborates with pharmaceutical and biotechnology companies to design study protocols, collect and analyze data, and prepare comprehensive study reports for regulatory submissions.

Headquartered in Maryland with additional facilities in California, Bioqual serves a global client base ranging from emerging biotech firms to large pharmaceutical corporations. Its geographically distributed laboratories enable scalable study execution and logistical flexibility. While detailed leadership information is not broadly disclosed, Bioqual’s management is led by seasoned professionals with extensive experience in preclinical development and immunology research.